• LAST PRICE
    1.0786
  • TODAY'S CHANGE (%)
    Trending Up0.0486 (4.7184%)
  • Bid / Lots
    1.0100/ 1
  • Ask / Lots
    1.1000/ 25
  • Open / Previous Close
    1.0120 / 1.0300
  • Day Range
    Low 1.0001
    High 1.0900
  • 52 Week Range
    Low 0.9802
    High 8.9851
  • Volume
    23,286
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 1.03
TimeVolumeELEV
09:57 ET5001.01
10:06 ET21771.0101
10:46 ET12001.0001
10:50 ET10001.0041
11:44 ET1001.01
12:30 ET3801.0016
12:43 ET35001.0198
12:57 ET101401.05
12:59 ET1001.03
01:12 ET1001.0148
01:14 ET3001.0399
01:21 ET2001.0384
02:15 ET2001.04
03:21 ET2001.0654
03:23 ET1001.09
03:32 ET1001.07
03:43 ET23201.0786
Data delayed at least 15 minutes.
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesELEV
Elevation Oncology Inc
25.1M
-0.4x
---
United StatesRGLS
Regulus Therapeutics Inc
25.2M
-0.7x
---
United StatesTNXP
Tonix Pharmaceuticals Holding Corp
24.3M
-0.1x
---
United StatesATNF
180 Life Sciences Corp
26.0M
1.0x
---
United StatesGRCL
Gracell Biotechnologies Inc
169.9M
-2.1x
---
United StatesOTLC
Oncotelic Therapeutics Inc
27.0M
4.3x
---
As of 2022-09-24

Company Information

Elevation Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of targeted therapeutics for the treatment of cancer in genomically-defined patient populations. It focuses on identifying oncogenic drivers with other driver alterations and in the conduct of clinical trials. Its lead drug development candidate, seribantumab, is an Anti-HER3 monoclonal antibody and potential targeted therapy for solid tumors driven by neuregulin-1 (NRG1) fusions, which are genomic alterations that are identified as oncogenic driver alterations. Its NRG1 is the primary activating ligand of HER3. The Company's clinical trial, CRESTONE, is a Phase II study of seribantumab in cancer patients with a solid tumor of any origin that expresses a genomic change called an NRG1 fusion.

Contact Information

Headquarters
888 Seventh Ave, 12Th FloorNEW YORK, NY, United States 10106
Phone
212-651-6380
Fax
---

Executives

Chairman of the Board
Steven Elms
Chief Executive Officer, Founder, Director
Shawn Leland
Chief Financial Officer
Joseph Ferra
Chief Scientific Officer
David Dornan
Vice President - Finance and Accounting
Tammy Furlong

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$25.1M
Revenue (TTM)
$0.00
Shares Outstanding
23.3M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-2.92
Book Value
$6.06
P/E Ratio
-0.4x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.